Funding Opportunity PAR-21-056 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Funding Opportunity PAR-21-057 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Funding Opportunity PAR-21-059 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Funding Opportunity PAR-21-078 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.

Up to £60,000 plus benefits and share options: Singular Talent: Expert in Genomics and Immunology? Want to get involved in some genuinely novel science targeting autoimmune diseases? Take a look at this..... Oxford, Oxfordshire (GB)

Notice NOT-HL-20-825 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-21-160 from the NIH Guide for Grants and Contracts. The purpose of this Request for Applications (RFA) is to solicit research that will help to identify and explain the mechanisms and pathways by which interventions targeting social drivers of mental illnesses affect the mental health and functioning of children and/or adolescents (ages 5-24 years) living in World Bank designated low- and middle-income countries (LMICs) . Studies should use innovative approaches to capture as much real-world complexity as possible in identifying and elucidating mechanisms and pathways that reduce risk for mental illnesses or improve mental health in children and/or adolescents.

Notice NOT-ES-21-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-21-106 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Funding Opportunity RFA-MH-21-105 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Notice NOT-MH-21-071 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-070 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-079 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-155

Funding Opportunity PAR-21-043 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial.

Funding Opportunity PAR-21-042 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.

Funding Opportunity PAR-21-041 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project

Adapts bioinformatics tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis.
From Medical College of Wisconsin - Wed, 18 Nov 2020 03:09:07 GMT - View all Milwaukee, WI jobs

The successful candidate will work closely with two teams – bioinformatics colleagues as well as our clinical analysis and reporting team.
From Medical College of Wisconsin - Wed, 18 Nov 2020 03:08:54 GMT - View all Milwaukee, WI jobs

Up to £45,000 depending on experience, with benefits and share options: Singular Talent: Molecular/Cellular Biologist with an immunology background? Want to spend your time exploring genomic dark matter for drug targets? Thought so..... Oxford, Oxfordshire (GB)

Funding Opportunity PAR-21-065 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.